CNC vs URGN · P/E 8.4, rev $103.52B vs rev $123.4M
Centene Corp (CNC) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Centene Corp (CNC) is a healthcare plans company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported CNC revenue for 2026-06-30 was $103.52B. Net income was $2.63B. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
CNC currently screens at market cap $28.19B and trailing P/E 8.4. URGN currently screens at market cap $1.61B.
Not investment advice. Open the CNC and URGN stock pages for the full models.
Not investment advice.